Short-acting ÃŸ2 agonists should be used as the initial treatment for COPD patients to relieve breathlessness.
COPD covers a range of chronic disorders that result in blocked airflow to the lungs.
palliative care is sadly lacking for patients with COPD.
In patients with asthma or COPD a lesser degree of systemic exposure to inhaled fluticasone propionate has been observed.
Early identification is a priority if the debilitating, disabling, life shortening and expensive consequences of severe COPD are to be avoided.